Edwards says EVOQUE tricuspid valve trial shows lower mortality at two years

Reuters03-30
Edwards says EVOQUE tricuspid valve trial shows lower mortality at two years
  • Edwards Lifesciences released new 2-year TRISCEND II trial data on EVOQUE transcatheter tricuspid valve replacement system at ACC.26.
  • Results extended 18-month findings previously presented at ESC 2025.
  • Data showed sustained near elimination of tricuspid regurgitation, improved health status.
  • Analyses reported no added device-related risk, lower all-cause mortality when accounting for patient crossover.
  • EVOQUE is marketed in US, Europe.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260330944749) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment